Switching from Semaglutide to Tirzepatide: What You Need to Ask First

Are semaglutide and tirzepatide interchangeable, or is a switch a bigger step than it sounds?

There is a common assumption that moving from one GLP-1 medicine to another is a bit like swapping brands of the same product. It is not quite that simple. Semaglutide (Wegovy) activates the GLP-1 receptor only, while tirzepatide (Mounjaro) activates both GLP-1 and GIP receptors simultaneously, the only dual-agonist weight-management medicine currently licensed in the UK. That difference in mechanism means your body responds differently, and the side-effect profile, even if broadly similar, is not identical.

Practically, a switch also means restarting a titration schedule. Tirzepatide begins at 2.5 mg regardless of which dose of semaglutide you were taking, because the starter dose is designed to help your system adjust to the new medicine rather than to deliver full therapeutic effect from week one. A prescriber who understands your treatment history will decide the pace from there. For a side-by-side look at how these medicines compare more broadly, the tirzepatide vs semaglutide comparison page goes through the evidence in detail.

The short answer is: yes, clinically possible, but it is a deliberate, supervised step, not a casual swap. The reasons why someone might consider it, and whether those reasons justify a change, are exactly what a prescriber weighs up.

What evidence is there that tirzepatide produces different results from semaglutide?

The clearest head-to-head data comes from SURMOUNT-5, a 72-week open-label trial involving 751 adults with obesity and no diabetes, published in the New England Journal of Medicine in 2025. Tirzepatide produced greater average weight reduction than semaglutide 2.4 mg across that period. NICE referenced indirect comparisons favouring tirzepatide in its appraisal of the medicine (NICE technology appraisal TA1026).

Earlier individual trial data adds context. SURMOUNT-1 showed average weight reductions of around 20–21% at the 15 mg dose over 72 weeks. STEP 1, which studied semaglutide 2.4 mg, showed approximately 15% average reduction over 68 weeks. The newer 7.2 mg semaglutide dose narrows that gap (trial data reported around 20.7% over 72 weeks) though that dose is very recent and head-to-head data against tirzepatide at equivalent doses is still emerging.

None of this tells you what will happen for you specifically. Clinical trials report averages across large groups; individual responses vary considerably depending on adherence, lifestyle factors, and biology. That is why the question of whether to switch (and to what dose) belongs in a consultation rather than in a comparison table alone.

How does a switch from semaglutide to tirzepatide actually happen?

There is no universal protocol stamped across every clinic, and anyone claiming to have a fixed rule for every patient should be treated with some caution. What good practice looks like, based on NHS England's guidance on weight-management injections, is this: the prescriber reviews why you want to switch, considers how long you have been on semaglutide, what dose you reached, and what results you have or have not seen. They also check for any contraindications specific to tirzepatide that may not have applied to semaglutide.

Timing matters too. Some prescribers prefer a short wash-out gap; others move directly from one medicine to the next. Neither is universally correct, it depends on clinical factors including your current dose level and how recently you last injected. The practical timing guide for switching from semaglutide to tirzepatide covers what this period typically looks like.

At nume, transfer patients provide evidence of their current treatment as part of our clinical review process. A GPhC-registered prescriber reads every submission personally. If a switch to Mounjaro is appropriate, treatment is prescribed and dispatched the same day for orders placed before 12pm. If you are also curious about switching in the other direction, the guide to switching from Mounjaro to semaglutide addresses that scenario separately.

Which medicine is right for you, and who decides?

Our prescribers hear this question regularly, usually from people who have plateaued on semaglutide and want to understand whether tirzepatide might do more. Sometimes it might. Sometimes the better answer is reviewing adherence, lifestyle factors, or dose optimisation on the current medicine first. There is no shortcut around that clinical conversation.

If you are currently on Wegovy and wondering whether to make a change, the page on whether switching from semaglutide to tirzepatide is right for you goes into the factors a prescriber weighs, and the broader Mounjaro vs Wegovy decision guide is useful context if you are earlier in the process. For a cost perspective, how the two medicines compare on price in the UK is worth reading before your consultation.

Which medicine suits you is a clinical decision our prescribers make with you, not something a comparison table can settle alone. Check your eligibility and start your free consultation to talk it through with our team.